The pharmacological landscape of obesity and metabolic syndrome management is undergoing an unprecedented evolution, driven primarily by the iterative engineering of incretin-based therapies. What began with the advent of mono-agonists such as liraglutide and semaglutide—which target the glucagon-like peptide-1 (GLP-1) receptor—has rapidly expanded into the realm of poly-agonism. The clinical success of dual GIP/GLP-1 receptor agonists like tirzepatide, and the potent phase 2 data emerging for triple GIP/GLP-1/glucagon receptor agonists like retatrutide, have validated the hypothesis that engaging multiple metabolic pathways simultaneously yields superior weight-loss and cardiometabolic outcomes. Into this highly competitive and scientifically rigorous arena enters an investigational compound known as Bioglutide, or NA-931, developed by Biomed Industries.
Bioglutide (NA-931) has drawn significant attention in the early stages of its development due to an extraordinarily ambitious mechanistic claim: it is described as a first-in-class, orally active “quadruple receptor agonist” targeting the GLP-1, GIP, glucagon, and Insulin-like Growth Factor 1 (IGF-1) receptors. If these claims translate robustly into peer-reviewed, reproducible clinical outcomes, NA-931 would represent a paradigm shift, theoretically combining profound appetite suppression and thermogenesis with muscle-sparing anabolic properties. However, a critical appraisal of the current literature reveals that public evidence for Bioglutide remains in its infancy. Much of the available data is confined to conference abstracts, clinical trial registry listings, and corporate press releases, with a notable absence of full, peer-reviewed publications detailing its precise medicinal chemistry, receptor-binding affinities, and long-term cardiovascular safety.
MOLECULAR IDENTITY, FORMULATION, AND THE DISCLOSURE GAP
In the rigorous discipline of peptide chemistry and pharmacology, the transition from mono-agonism to dual or triple agonism requires exquisite structural balancing. Hormones like GLP-1, GIP, and glucagon are structurally related peptides that bind to Class B G-protein-coupled receptors (GPCRs). Creating a single unimolecular peptide that binds with tuned affinity to all three of these GPCRs—as seen with retatrutide—is a masterclass in rational drug design, requiring specific amino acid substitutions and lipid conjugations to optimize half-life and receptor agonism.4
NA-931 is publicly characterized as a “small molecule” or “oral peptide” quadruple agonist. This introduces a significant scientific disclosure gap. While cross-reactivity among the GLP-1, GIP, and glucagon receptors is biochemically plausible due to their structural homology, the IGF-1 receptor belongs to an entirely different class of cell-surface receptors: the receptor tyrosine kinases (RTKs). RTKs operate via ligand-induced dimerization and autophosphorylation, a mechanism fundamentally distinct from the cAMP-mediated intracellular signaling of incretin GPCRs.
“The architectural requirements for a single molecule to act as a high-affinity agonist at both Class B GPCRs (the incretin and glucagon receptors) and a receptor tyrosine kinase (the IGF-1 receptor) are biochemically unprecedented in public literature. Without published crystal structures, cryogenic electron microscopy (cryo-EM) data, or detailed pharmacodynamic binding assays (Ki/Kd values), the exact molecular identity of NA-931 remains an area of profound scientific intrigue and necessitates rigorous independent validation.”
Furthermore, delivering a multi-receptor agonist orally presents massive pharmacokinetic hurdles. Gastrointestinal peptidases rapidly degrade proteinaceous therapeutics, and the mucosal barrier prevents the systemic absorption of large molecular weight compounds. While oral semaglutide successfully overcame this using the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), the specific absorption technology or small-molecule characteristics that allow NA-931 to achieve its reported oral bioavailability remain proprietary and unpublished in independent peer-reviewed literature.
MECHANISTIC RATIONALE FOR EACH RECEPTOR PATHWAY
The theoretical framework underlying a quadruple agonist relies on the synergistic, and sometimes counterbalancing, physiological effects of the four target hormones. By engaging multiple nodes of the metabolic network, NA-931 attempts to establish a new homeostatic setpoint for body weight and energy expenditure.
GLP-1: Satiety and Glycemic Control
The foundation of modern obesity pharmacotherapy is GLP-1 receptor agonism. GLP-1 is an endogenous incretin hormone secreted by intestinal L-cells that enhances glucose-dependent insulin secretion, inhibits postprandial glucagon release, and profoundly delays gastric emptying. Centrally, GLP-1 crosses the blood-brain barrier to stimulate pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus, leading to robust appetite suppression and caloric deficit.1 NA-931 presumably leverages this established pathway as the primary driver of weight loss.
GIP: Incretin Synergy
Glucose-dependent insulinotropic polypeptide (GIP) has historically been overshadowed by GLP-1, but the success of tirzepatide illuminated its therapeutic value.2 GIP is secreted by intestinal K-cells and acts synergistically with GLP-1 to enhance insulin secretion. Moreover, GIP receptors are densely expressed in adipose tissue and the central nervous system. Co-agonism of GIP and GLP-1 appears to mitigate some of the nausea and gastrointestinal distress typically associated with high-dose GLP-1 mono-therapies, while amplifying central anorexigenic signaling.4
Glucagon Receptor: Energy Expenditure and Lipid Mobilization
Historically viewed strictly as a counter-regulatory hormone that increases blood glucose via hepatic glycogenolysis and gluconeogenesis, glucagon has recently been rehabilitated as a powerful tool in obesity management. Glucagon receptor agonism increases energy expenditure, promotes hepatic lipid mobilization (reducing hepatic steatosis), and stimulates brown adipose tissue thermogenesis.5 The inherent risk of glucagon—hyperglycemia—is effectively buffered in multi-agonists by the potent insulinotropic actions of the concurrent GLP-1 and GIP agonism. This triad is the basis for retatrutide’s efficacy.3
IGF-1 Pathway: Theoretical Muscle Preservation
The most distinct and unconventional claim of NA-931 is its agonism of the IGF-1 receptor. A well-documented limitation of rapid, pharmacologically induced weight loss (as seen with semaglutide and tirzepatide) is the concurrent loss of lean muscle mass, which can comprise up to 25-40% of total weight lost. IGF-1 is a highly anabolic hormone that stimulates muscle protein synthesis via the PI3K/Akt/mTOR pathway and inhibits protein degradation pathways. Theoretical agonism of this receptor is proposed to preserve lean muscle tissue during the extreme caloric deficit induced by the incretin pathways. However, it must be noted that systemic IGF-1 agonism also carries theoretical risks regarding cellular proliferation and mitogenesis, making long-term safety data paramount.
ORAL PHARMACOLOGY AND PHARMACOKINETIC SIGNIFICANCE
The clinical utility of a highly effective obesity medication is often bottlenecked by patient compliance, which is heavily influenced by the route of administration. Currently, the most effective agents (tirzepatide, retatrutide, high-dose semaglutide) require subcutaneous injections. While oral semaglutide exists, its efficacy for weight loss at currently approved doses is generally less robust than its injectable counterpart, largely due to fractional absorption rates (often less than 1%) even with permeation enhancers.
If NA-931 genuinely represents an oral agent capable of delivering double-digit percentage weight loss, it would drastically alter the treatment algorithm. Oral administration removes the stigma and discomfort of injections, eliminates cold-chain storage requirements, and potentially lowers manufacturing and distribution barriers. However, achieving steady-state pharmacokinetics with an oral peptide or complex small molecule is notoriously difficult. Fluctuations in gastric pH, the presence of food, and individual variations in mucosal permeability can lead to erratic drug exposure, increasing the risk of either sub-therapeutic dosing or unexpected adverse events. The company reports that NA-931 can be taken without regard to meal timing—a significant logistical advantage over oral semaglutide if validated in larger cohorts.10
EARLY CLINICAL EVIDENCE: A CRITICAL APPRAISAL
The clinical data publicly available for NA-931 currently stems from early-phase trials presented at major endocrine conferences, supplemented by clinical trial registry data. It is vital to interpret these findings with the caveat that they have not yet undergone the stringent peer-review process required for publication in top-tier medical journals.
Phase 1 Data (NCT06615700)
Data from a Phase 1 randomized, double-blind, placebo-controlled multiple-ascending dose (MAD) study (NCT06615700) was reported in an abstract (143-OR) for the American Diabetes Association (ADA) 2025 Scientific Sessions.8 Over a 28-day period involving 74 subjects, NA-931 demonstrated dose-dependent reductions in mean body weight up to 6.4%. The abstract reported that up to 63% of treated subjects achieved ≥5% weight loss. Treatment-emergent adverse events (TEAEs) were described as mostly mild or insignificant gastrointestinal issues, with no reported muscle loss—though the specific methodologies used to assess body composition (e.g., DEXA or bioelectrical impedance) in this brief window were not deeply detailed in the abstract.
Phase 2 Data (NCT06564753)
More substantial claims arise from a 13-week Phase 2 randomized, double-blind, placebo-controlled study (NCT06564753) involving 125 adults with obesity or overweight status with comorbidities. According to abstract 2189-LB (ADA 2025) and subsequent company press materials for the ENDO 2025 conference, the 13-week study yielded striking topline results.69
“Topline reports describe dose-dependent weight loss reaching up to approximately 13.8% to 14.8% at the 150 mg daily oral dose (with slight variations appearing across different corporate and abstract releases). Up to 72% of subjects treated with NA-931 reportedly achieved at least 12% weight loss, compared to 2% in the placebo cohort. Crucially, the developers claim that this weight reduction was achieved without observable muscle loss, attributing this tissue-sparing effect to the IGF-1 receptor agonism.”10
Safety data from this Phase 2 trial characterized GI adverse events—such as nausea, vomiting, and diarrhea—as predominantly mild, with incidence rates (e.g., 7.3% for mild nausea/vomiting) appearing favorably low compared to historical data from early incretin trials. However, full transparency of dropout rates, exact pharmacokinetic profiles, and detailed cardiometabolic markers (lipids, heart rate, blood pressure) awaits comprehensive peer-reviewed publication.
COMPARATIVE ANALYSIS: MECHANISM, ROUTE, AND MATURITY
Contextualizing NA-931 requires comparison against the established and emerging titans of obesity pharmacotherapy. Liraglutide (a daily subcutaneous GLP-1 agonist) and semaglutide (a weekly subcutaneous GLP-1 agonist) form the baseline of efficacy, yielding approximately 8% and 15% body weight loss, respectively, over 68 weeks. Both possess monumental, multi-year cardiovascular outcome data confirming their safety and cardioprotective benefits.1
Tirzepatide (weekly subcutaneous GIP/GLP-1) elevates the efficacy ceiling, demonstrating upwards of 20-22% weight loss over 72 weeks in the SURMOUNT-1 trial.2 Retatrutide (weekly subcutaneous GIP/GLP-1/Glucagon) currently holds the clinical high-water mark in Phase 2 data, showing over 24% weight loss at 48 weeks, alongside profound reductions in hepatic steatosis.3
NA-931 proposes to match or exceed the velocity of retatrutide’s weight loss (approaching 14% at merely 13 weeks is an exceptionally rapid trajectory), while offering the unprecedented conveniences of oral administration and IGF-1-mediated muscle preservation. However, regarding evidence maturity, NA-931 is vastly eclipsed by the others. Liraglutide, semaglutide, and tirzepatide are backed by thousands of peer-reviewed pages, decades of clinical exposure, and rigorous FDA/EMA scrutiny. NA-931 remains an early-stage candidate whose most extraordinary claims rely on preliminary, pre-publication datasets.
HYPE VERSUS EVIDENCE: THE PATH FORWARD
The concept of an oral quadruple agonist that shreds adipose tissue while shielding lean muscle is the holy grail of metabolic medicine. The excitement surrounding NA-931 is entirely justified by the theoretical elegance of its proposed mechanism. Nevertheless, scientific rigor demands that hype be tempered by evidence.
Several critical milestones must be met before NA-931 can be fully validated. First, the structural biology and precise pharmacological binding constants (in vitro functional assays for cAMP accumulation and RTK phosphorylation) must be published to satisfy the scientific community regarding how one molecule activates four highly divergent receptors. Second, independent replication of the Phase 2 efficacy data in large, multi-center, international Phase 3 cohorts is mandatory. Third, detailed body composition analyses (using serial DEXA or MRI scans) must be provided to substantiate the muscle-sparing claims. Finally, long-term safety—particularly concerning cardiovascular outcomes, pancreatic safety, and the oncologic theoretical risks associated with systemic IGF-1 pathway modulation—must be tracked over years, not weeks.
CONCLUSION
Bioglutide (NA-931) represents a fascinating, highly ambitious foray into the next generation of metabolic pharmacotherapy. By purportedly combining GLP-1, GIP, and glucagon agonism with the novel inclusion of IGF-1 receptor activation, it seeks to optimize the ratio of fat-to-muscle loss while offering the immense logistical benefit of oral administration. The preliminary Phase 1 and Phase 2 data presented at recent symposia describe a highly potent, rapid-acting weight-loss agent with a favorable early tolerability profile.
However, the current public understanding of NA-931 is constrained by a lack of peer-reviewed literature and full structural disclosure. As the compound advances toward Phase 3 clinical trials, the medical and scientific communities will eagerly await the robust, transparent datasets necessary to confirm whether Bioglutide is indeed the revolutionary metabolic modulator it aims to be, or if the unprecedented complexity of quadruple agonism introduces unforeseen pharmacological hurdles.
REFERENCES
1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Cell Metabolism. 2018;27(4):740-756.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
3. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526.
4. Zhang J, Sanan S, Csanalosi M, et al. Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management. Endocrinology. 2025;166(11):bqaf130.
5. Sanchez-Garrido MA, Brandt SJ, Clemmensen C, et al. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851-1861.
6. ClinicalTrials.gov. Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-Related Comorbid Condition. Identifier: NCT06564753.
7. ClinicalTrials.gov. A Study to Evaluate NA-931 in Healthy Overweight/Obese Participants. Identifier: NCT06615700.
8. Tran LL. 143-OR: NA-931, a Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss. Diabetes. 2025;74(Supplement_1).
9. Tran LL. 2189-LB: Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese with at Least One Weight-Related Comorbid Condition. Diabetes. 2025;74(Supplement_1).
10. Biomed Industries, Inc. Corporate press releases and NA-931 product disclosures presented at ADA 2025 and ENDO 2025. Available via company publications and EIN Presswire distributions.
Disclaimer: This article is intended strictly for research and educational review purposes. The compound discussed (NA-931 / Bioglutide) is an investigational agent currently in clinical trials and has not been approved by the FDA, EMA, or any other regulatory body for the treatment of obesity, type 2 diabetes, or any other medical condition. The information presented herein relies heavily on preliminary clinical data, conference abstracts, and manufacturer press releases that have not yet undergone full independent peer review. This document does not constitute medical advice, nor should it be used to guide clinical practice or personal health decisions.
Bioglutide NA-931 is studied for its interaction with GLP-1 receptors and its role in glucose metabolism, insulin signaling, and energy balance in experimental models.
It mimics GLP-1 activity, activating incretin pathways associated with glucose-dependent insulin signaling and metabolic regulation.
It is studied in pathways related to insulin secretion, glucagon modulation, gastric emptying, appetite signaling, and cardiometabolic regulation.
Yes, it is engineered as a long-acting GLP-1 analog, allowing sustained receptor interaction in research settings.
Unlike endogenous GLP-1, it is structurally modified to resist rapid enzymatic degradation and prolong signaling effects.
It is used to investigate incretin biology, metabolic pathways, and long-acting GLP-1 receptor activation.
PMID:
19092145 — GLP-1 receptor agonists and metabolic regulation
19667100 — Incretin-based therapies and glucose control mechanisms
21325430 — GLP-1 analogs and insulin signaling pathways
22686409 — Long-acting GLP-1 receptor agonist pharmacology
24824548 — GLP-1 effects on appetite and energy balance
25651247 — GLP-1 receptor activation and cardiometabolic pathways
28235715 — Advances in GLP-1 analog design and stability
30760106 — GLP-1 signaling and metabolic homeostasis
Tirzepatide: Dual GIP and GLP-1 Receptor Agonism and Integrated Incretin Pathway Signaling
Retatrutide — Triple Agonist Research Article
Semaglutide : GLP-1 Receptor Agonism, Incretin Signaling, and Metabolic Regulation
Mazdutide : Dual GLP‑1 and Glucagon Receptor Activation in Metabolic and Lipid Regulation Research
